Table 3.
The impact of investigated polymorphisms on constipation anytime during the first four weeks of tramadol treatment (N = 99)
| SNP | Genotype | Constipation anytime N (%) | OR (95% CI) | P | OR (95% CI)adj | Padj |
|---|---|---|---|---|---|---|
| OPRM1 rs1799971 | AA | 30 (40) | Ref. | Ref. | ||
| AG+GG | 18 (75) | 4.5 (1.6–12.64) | 0.004 | 4.31 (1.52–12.17) | 0.006 | |
| OPRM1 rs677830 | CC | 24 (48) | Ref. | Ref. | ||
| CT+TT | 24 (49) | 1.04 (0.47–2.29) | 0.922 | 0.98 (0.44–2.19) | 0.964 | |
| MIR23B rs1011784 | CC | 29 (50) | Ref. | Ref. | ||
| CG | 16 (50) | 1 (0.42–2.37) | 1.000 | 0.96 (0.4–2.31) | 0.930 | |
| GG | 3 (37.5) | 0.6 (0.13–2.75) | 0.510 | 0.46 (0.1–2.23) | 0.338 | |
| CG+GG | 19 (47.5) | 0.9 (0.4–2.03) | 0.808 | 0.84 (0.37–1.91) | 0.676 | |
| MIR107 rs2296616 | GG | 11 (57.9) | Ref. | Ref. | ||
| GA | 23 (48.9) | 0.7 (0.24–2.04) | 0.511 | 0.73 (0.25–2.16) | 0.566 | |
| AA | 14 (42.4) | 0.54 (0.17–1.68) | 0.285 | 0.53 (0.17–1.67) | 0.276 | |
| GA+AA | 37 (46.3) | 0.63 (0.23–1.72) | 0.364 | 0.64 (0.23–1.77) | 0.386 |
adj = adjustment for tramadol dose; N = sample size; OR = odds ratio; SNP = single nucleotide polymorphism; 95% CI = 95% confidence interval